BidaskClub lowered shares of Retrophin (NASDAQ:RTRX) from a sell rating to a strong sell rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other analysts have also commented on RTRX. ValuEngine lowered Retrophin from a buy rating to a hold rating in a report on Thursday, April 18th. William Blair reaffirmed an outperform rating on shares of Retrophin in a report on Wednesday, April 17th. Barclays initiated coverage on Retrophin in a report on Monday, April 22nd. They set an overweight rating and a $36.00 target price on the stock. Finally, Zacks Investment Research lowered Retrophin from a hold rating to a sell rating in a report on Tuesday, May 14th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $44.50.

Retrophin stock opened at $20.60 on Friday. The firm has a market capitalization of $832.46 million, a price-to-earnings ratio of -8.11 and a beta of 0.93. Retrophin has a 52 week low of $17.53 and a 52 week high of $33.00. The business’s 50-day moving average is $19.19. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57.

Retrophin (NASDAQ:RTRX) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.41). The company had revenue of $39.57 million for the quarter, compared to analyst estimates of $41.40 million. Retrophin had a negative return on equity of 41.38% and a negative net margin of 75.75%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the business earned ($0.14) earnings per share. On average, sell-side analysts anticipate that Retrophin will post -3.02 earnings per share for the current fiscal year.

In other Retrophin news, insider William E. Rote sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $17.77, for a total value of $28,876.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steve Aselage sold 3,676 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $17.81, for a total value of $65,469.56. Following the completion of the sale, the director now directly owns 257,804 shares in the company, valued at $4,591,489.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,819 shares of company stock worth $194,503. 4.32% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of RTRX. SG Americas Securities LLC acquired a new stake in Retrophin in the first quarter valued at approximately $143,000. Campbell & CO Investment Adviser LLC acquired a new stake in Retrophin in the first quarter valued at approximately $217,000. Metropolitan Life Insurance Co. NY grew its holdings in Retrophin by 318.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,785 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 10,491 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in Retrophin in the first quarter valued at approximately $327,000. Finally, Legal & General Group Plc grew its holdings in Retrophin by 17.2% in the fourth quarter. Legal & General Group Plc now owns 15,866 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 2,325 shares during the period.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What are some reasons analysts would give stocks a buy rating?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.